PlaqueTec, a company aiming to advance precision medicine for coronary artery disease, has raised £6.4 million in equity financing.

The round was led by Lord Moynihan of Chelsea alongside the Future Fund, with support from existing investors.

The Cambridge firm will use the funding for its ongoing BIOPATTERN trial, designed to improve understanding of CAD pathobiology and how it varies between individuals, and to build BIOCARTA, its novel biomarker discovery tool.

BIOCARTA is a bioinformatics discovery platform that interrogates data and groups patients with CAD into endotypes with defined signatures of the disease. BIOCARTA correlates in vivo biomarkers localising at the disease site with plaque imaging, genomic analysis, blood biochemistry and clinical and demographic phenotypes to further enhance a unique understanding of disease.

£247m takeover at Cambridge breast cancer tech firm

PlaqueTec is using BIOCARTA to identify biomarkers to accurately assess patients and therefore inform more targeted therapeutic interventions, transforming patient care.

At the heart of BIOCARTA is PlaqueTec’s BIOPATTERN trial, which uses the company’s proprietary blood sampling device, the Liquid Biopsy System, to collect samples containing biomolecules localising at or being released by coronary plaque. 

“CAD is a leading cause of death worldwide and represents an area with significant unmet medical need,” said chairman Martin Stapleton. 

“The continued support from our existing investors and additional funding from the Future Fund reinforces the potential of our technology and BIOCARTA database, and brings us closer to achieving our vision of opening a new frontier of precision medicine for millions of patients with CAD worldwide.”

Locate Bio raises £9.2m to develop bone graft substitute